Optimized TrkB Agonist Ameliorates Alzheimer’s Disease Pathologies and Improves Cognitive Functions via Inhibiting Delta-Secretase
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
High Resolution Image Download MS PowerPoint Slide BDNF/TrkB neurotropic pathway, essential for neural synaptic plasticity and survival, is deficient in neurodegenerative diseases including Alzheimer’s disease (AD). Our previous works support that BDNF diminishes AD pathologies by inhibiting delta-secretase, a crucial age-dependent protease that simultaneously cleaves both APP and Tau and promotes AD pathologies, via Akt phosphorylation. Small molecular TrkB receptor agonist 7,8-dihydroxyflavone (7,8-DHF) binds and activates the receptor and its downstream signaling, exerting therapeutic efficacy toward AD. In the current study, we optimize 7,8-DHF pharmacokinetic characteristics via medicinal chemistry to obtain a synthetic derivative CF 3 CN that interacts with the TrkB LRM/CC2 domain. CF 3 CN possesses improved druglike features, including oral bioavailability and half-life, compared to those of the lead compound. CF 3 CN activates TrkB neurotrophic signaling in primary neurons and mouse brains. Oral administration of CF 3 CN blocks delta-secretase activation, attenuates AD pathologies, and alleviates cognitive dysfunctions in 5xFAD. Notably, chronic treatment of CF 3 CN reveals no demonstrable toxicity. Hence, CF 3 CN represents a promising preclinical candidate for treating the devastating neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034
Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00014-9 · Cited by 874
Vassar, R., Kovacs, D. M., Yan, R., & Wong, P. C. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3657-09.2009 · Cited by 577
Devi, L., & Ohno, M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.191 · Cited by 282
Zhang, Z., Liu, X., Schroeder, J. P., Chan, C.-B., Song, M., Yu, S. P., Weinshenker, D., & Ye, K. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.243 · Cited by 242
Self-citationPrelimbic cortical BDNF is required for memory of learned fear but not extinction or innate fear
Choi, D. C., Maguschak, K. A., Ye, K., Jang, S.-W., Myers, K. M., & Ressler, K. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909359107 · Cited by 212
Self-citationLiu, X., Chan, C.-B., Jang, S.-W., Pradoldej, S., Huang, J., He, K., Phun, L. H., France, S., Xiao, G., Jia, Y., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101206p · Cited by 208
Self-citationNGF and BDNF signaling control amyloidogenic route and Aβ production in hippocampal neurons
Matrone, C., Ciotti, M. T., Mercanti, D., Marolda, R., & Calissano, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806133105 · Cited by 169
Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer’s disease
Zhang, Z., Obianyo, O., Dall, E., Du, Y., Fu, H., Liu, X., Kang, S. S., Song, M., Yu, S.-P., Cabrele, C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14740 · Cited by 146
Self-citation
Cited by
TrkB/BDNF signaling pathway and its small molecular agonists in CNS injury
Wang, Y., Liang, J., Xu, B., Yang, J., Wu, Z., & Cheng, L. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122282 · Cited by 152
C/EBPβ/AEP Signaling Drives Alzheimer’s Disease Pathogenesis
Xiong, J., Zhang, Z., & Ye, K. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01025-w · Cited by 37
Self-citationPositive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease
Forsell, P., Parrado Fernández, C., Nilsson, B., Sandin, J., Nordvall, G., & Segerdahl, M. (2024) · Pharmaceuticals · doi:10.3390/ph17080997 · Cited by 14
Small-Molecule Trk Agonists: Where Do We Go from Here?
Thompson, T. S., Sefiani, A., & Burgess, K. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02365 · Cited by 13
Metadata
- Authors
- Chen, C., Ahn, E. H., Liu, X., Wang, Z.-H., Luo, S., Liao, J., & Ye, K.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-06-09
- Volume
- 12
- Issue
- 13
- Pages
- 2448-2461
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W3168942664
- Cited by
- 41
- References
- 11
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimized TrkB Agonist Ameliorates Alzheimer’s Disease Pathologies and Improves Cognitive Functions via Inhibiting Delta-Secretase. https://app.cochat.ai/papers/10.1021/acschemneuro.1c00181
- The paper
- Chen, C., Ahn, E. H., Liu, X., Wang, Z.-H., Luo, S., Liao, J., & Ye, K. (2021). Optimized TrkB Agonist Ameliorates Alzheimer’s Disease Pathologies and Improves Cognitive Functions via Inhibiting Delta-Secretase. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.1c00181
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.